Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
None of that investigation helps Cytodyn in any way. A distraction at best. Because companies succeed or fail on their own. For example if Leronlimab is unable to cure COVID (my own conclusion based on past disclosed data and lack of transparency from the company on closed trials and interims) there is nothing that will save CYDY stock from oblivion. Now any stock promoter who has pumped this stock without disclosing a payment by the company will be investigated and convicted by the SEC, as it is illegal. They shall not believe they are protected by anonymity, everything is logged. But my point is that, even if that will make me happy to know that justice has been served, these are side shows - they won't change anything for the stock that will go to $0.25 once the failures combine with the bankruptcy to trigger a mass investors exodus.
Hmm so if that were so easy, if the sole presence of OLEs and eINDs were 100% sure to guarantee a drug approval, why hasn't the Cytodyn stock reacted by shooting to $20+?
=> The market is telling us something....
Now kgromax knows why the market is not reacting (nor the FDA...)...and it has something to see with statistics...basically the trial has bad combined mortality statistics...
Nope. OLE and eINDs are not at all predictors of approval. Sorry, there are “ways”.
My opinion is that Samantha Mottet is currently cutting a deal with the SEC and FBI. Same for some of the key doctors.
My opinion is that Cytodyn is a fraud. I have worked in a major investment bank as a quant, including a stint in fraud detection on a very large scale. Have then spent 10 years as an independant (for my own profit) short-selling more than 100 frauds. Cytodyn matches all the patterns I know of. All of them.
The need for so many explanations to rationalize the fact that Cytodyn has ZERO approval after years of such promises is a big telltale sign. A much shorter alternative explanation: the company is a fraud.
I can confirm BlackOps is right. I heard a rumor that the SEC is investigating Cytodyn and BlackOps for illegally promoting the stock without disclosing the relationship
Like Cytodyn’s CEO dumping 88% of his shares while he was promising to new external investors great outcomes for CYDY upcoming trials and HIV approval? That kind of thing?
Cytodyn is in my opinion a stock market fraud whose sole purpose is to enrich its insiders at the expense of minority shareholders. Leronlimab has never been approved for anything despite promises it would be in 2018, 2019, 2020, etc...
ZERO COMPANY PR - BAD OMEN
Nader Pourhassan the CEO is hiding under his desk.
While his CMO has prepared a massive share dump.
First come first served.
That's a great find. Cytodyn's CEO behavior is fraud in my opinion. ALL THE SIGNS ARE THERE
It's the elephant in the middle of the room.
Excepted Cytodyn has always failed getting any regulatory or NASDAQ approval despite tons of suggestions this was just a matter of weeks or months
This simple fact - the elephant in the middle of the room - destroys all the rationale.
Nothing, no word games or literature from the company management and its promotion firm minions can hide that.
Just ask the FDA, MHRA or any other regulators. They have all turned down politely CD10. Coulé.
Nope. It is following exactly the CD10 script. Which ended as you know revealing that it was a big failure, with EVERY regulator. The company is just buying time because it is in a difficult financial situation and also because insiders and related friends & families hold shares that they would need to dump before the crash
Leronlimab miracle was promised in 2018. Wait, 2019. Wait, Q1 2020. Wait, June. No, July. Nope, August. September? Nope. October? No. Etc etc... it's the difference between the sad Cytodyn reality and the projections of investors. But, wait, we don't have the exact proof that the CEO and the CFO sold >87% of their stock. Until we see every ID of every share sold, when and how, together with a written testimony of the broker, banker, market maker and priest, we shall discard that crucial piece of information.
6 months afer, the CD10 failed trial results have NOT been disclosed. Same for the HIV BLA FDA letter content. Same for every regulator answer. Same for everything in fact. No need for Las Vegas to see the issue
Do we have the CD10 trial results? The CD12 trial results? The exact response from the FDA on the HIV BLA? The exact UK, Canada, Mexico, Thailand answers? The NASDAQ exact answer? Nope. Yet, theories are made by many that they are all good for Cytodyn, without any proof or any evidence. Form 144 has no reason to be a lesser evidence. I consider it is even the writing on the wall. This is bad for Cytodyn. She is the CMO spouse. It’s over and when all the proofs are available it will be way too late, that will be during the class action lawsuit when the stock is at $0.2
PS: dont worry still tonight Cytodyn’s Friday Night Dump will bring some of the pieces of evidences you have requested, along probably with a toxic loan partition and a missed primary endpoint
Ah ah ah a “fat finger” or a “future sale”. Any theory to support Cytodyn’s price is acceptable here as long as it is ... long. But of course the basic and far simpler theory that she is just selling as we speak...is not acceptable. I feel a huge disappointment coming. And not for shorts.
Analogies are useless ... because the Chief’s Medical Officers’s spouse has very probably sold a lot of shares. She has zero confidence.
Or the gold is bad lead and Cytodyn is going down the drain
Or Cytodyn has indeed failed the COVID CD12 trial, like the previous COVID CD10 trial
Excepted it will never hit $45. Bye bye mortgage, condo and plane
CD10 / NEWS2 as every professional statistican knows are pure datamining.
That means: the company, Cytodyn, handpicked out of 20 statistics (and probably much more, they never disclosed exactly how deep they datamined and how many subsets of patients were analyzed) the most favorable one.
It's pretty obvious really for a statistician. It's called picking the best card out of a 52 cards set and marketing it as a "win". Anybody could do it. Give me 52 cards and I can show you an ace.
What is much harder: force me to pick a single card, BLINDED. That will be MUCH harder for me to obtain an ace.
CD10 was a failure. The proof is: despite the huge pandemic crisis, zero countriies have approved Leronlimab based on CD10 detailed data (that, today, HAS NOT BEEN DISCLOSED TO SHAREHOLDERS). It's pretty simple.
Because its zero-communication on the COVID trial is revealing its failure
The choice is between the stock market disaster that Cytodyn may be and the stock market fraud that Cytodyn is (in my opinion)
All the signs are there. Delayed disclosure, paid promotion, delayed disclosure, paid promotion, delayed disclosure, etc....
If that isn't clear. It's the previous (failed) CD10 trial all over again, same tricks, same outcome. It's a fraud.
Week 3 reached yet ZERO CEO communication
You know what this means:
Trial has failed, consistent with past « sure thing » promises from the company which ALL magically failed
Crash coming.
Difference with last summer:
company now trapped with toxic loans and Samsung due bills
The fall will be sudden and violent
What Cytodyn's management is doing is called by market pros "moving the goalpost".
It's a fine art:
- "CD12 results in mid-jan"
- "Plus 2 weeks"
- "Plus 2 weeks to then start the real work which will take 2-3 weeks"
- "We filed mock data with the FDA"
- No news
- "We got rejected but in 1-2 weeks it's resubmitted"
- No news
- "Maybe we will resubmit in September"
- "We will resubmit by year end"
- "We will resubmit around mid-next year"
- ...
"Long haulers" is how Cytodyn's management calls this syndrom
All pump & dump frauds end up in panics, crashes and lawsuits. It's only the beginning.
Plus their death/alive status has been already compiled in the safety reports. The only missing data is the arm key which was already compiled upon recruitment assignment to arms
The CEO sold 88% of this stocks while advertising "very promising" results in parallel and the CFO sold 87% of this stocks while negotiating toxic loan debt, so I think their cash has gone far, far away from Cytodyn. The shareholders will never see it again. It was their cash initially, now it is probably on a US or Caribbean bank account, insulated from the failures factory.
It's always like that with Nader Pourhassan the CEO. He has all the fraud patterns. It's just a never ending story, it has been like that for years: next month, next quarter, next year, etc... it's in my opinion a Merry Go Round fraud. Always a little delay, and always a new shiny thing. That's exactly what he did today, as everytime: a delay, and a new shiny thing.
Here is a FACT: Cytodyn must repays $7.5 millions to its toxic lender before month end
Question: how can they repay such a large amount?
Tip: last month they paid in shares, not in cash, at ... $3.4 a share
Question #2: how can the toxic lender convert these shares back to cash?
A fake release right AT THE SAME TIME or AFTER the $7.5 million toxic loan January debt conversion announcement.
By fake, I mean like this summer's CD10 releases ("great safety", "impressive results") which were talking about everything but the missed primary endpoint and triggered a stock crash.
By January prepartition announcement, I mean that the January $7.5 million they owe to their toxic lender (as in Feb, March, etc...it's killing their treasury) is based on my estimates way above their available cash due to the other required payments and burn rate. So I think they are negotiating currently another prepartition exchange of debt for equity to get rid of the January repayment. They need to settle a price for the equity shares offered to the lender as part of the conversion. Last prepartition in December was a blood bath ($3.4 a share!). This is not an easy discussion and I am convinced they want it closed and signed before the upcoming stock crash when shareholders will read about CD12 disappointing results. Otherwise they are at the mercy of the toxic lender who will request an even lower conversion price...
Their loan contract states that the $7.5 million repayment has to occur in January (in each calendar month in fact), which leaves a couple days maximum.
I expect 22% mortality for both arms, plus or minus a couple % point for each (due to chance only).
So...no statistical significance, and the Leronlimab mode of action does not work as expected before.
Yet another study indicates that the COVID trial is about to fail:
Details here
This is the third analysis I post. Based on top-notch worldwide and US-centric papers as usual. All these analysis converge toward the exact same conclusion: the level of placebo mortality required by Cytodyn to make its COVID trial successful (35% mortality) seems completely out of reach. ALL Severe/Critical benchmarks indicate a range of 12-24% maximum.
Cytodyn has botched this trial in my opinion for several reasons, the most important one being that Leronlimab's hypothetical mode of action is not working as expected against COVID. One of the mechanisms in the MOA must be different in reality, preventing Leronlimab from working as expected.
There are other reasons I believe this, some methodological. In particular they shall not have excluded high-risk critical patients, which represent 50-60% of ICU COVID patients and would have allowed to reach statistical significance way faster if ever Leronlimab had worked (which, still, is not my belief reading these numbers...). Cytodyn is the only sponsor I have found (across 50+) that excludes so many patients from ICUs. I don't know why they did that but it certainly also paved the way to failure.
Excepted across 50+ studies in every modern country, there are NONE that has the level of mortality for Severe/Critical patients required in the Cytodyn placebo arm to have 45 deaths there. It is just so inconsistent, by such a wide margin, it doesn't fly.
Having seen a hundred pump & dump frauds (what I am 100% convinced Cytodyn is, it matches all the patterns), here is how all these frauds end: a loud class action lawsuit by scammed shareholders against the company management. They will be able to retrieve a very limited % of their initial investment, and that's all.
These are qualitative facts. But the quantitative facts (disclosed combined Cytodyn trial mortality and COVID benchmark papers for the placebo arm) all indicate the trial has most probably failed. This is phase III, not an ealier phase. For a phase III the FDA is looking for hard numbers, not medical theories (M.D. theories and feedback are good for phase I or II but cannot cut it further).
The reason why the COVID trial is most probably a failure is already available to any interested investor or short-seller. It's pretty simple:
the COVID trial had way too many combined deaths, with Leronlimab having 2/3rd of patients, compared to placebo COVID benchmarks. It doesn't support the theory that Leronlimab has an effect on COVID.
Detailed analysis is available there.
I performed other analysis based on countless research papers before and they all lead to the same conclusion.
No. The Notice of Effectiveness references the ID of the initial filing which has become "effective". And this is...the S-3 preparing millions of shares for Cytodyn's toxic lender, so that he can dump them on the tiny OTC stock market. This is once again bad news. But that was already known when the S-3 was filed. Nothing unexpected or new.